The long‐acting <scp>anti‐C5</scp> ravulizumab results in <scp>C3</scp> binding to <scp>PNH</scp> red cells similar to its parental molecule eculizumab
Michela Sica, Federica Barone, Caterina Nannelli, Patrizia Ricci, Luana Marano, Maria De Angioletti, Eros Di Bona, Antonio M. Risitano, Rosario Notaro
Abstract
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.
Topics & Concepts
EculizumabHaemolysisMedicineComplement systemComplement component 5PopulationImmunologyInternal medicineAntibodyEnvironmental healthComplement system in diseasesBlood groups and transfusionRenal Diseases and Glomerulopathies